Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring.

Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care.

The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques.

Its portfolio includes technologies designed for nonsurgical replacement of heart valves.

The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve.

The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settingEdwards Lifesciences (Israel) Ltd operates as a subsidiary of Edwards Lifesciences Corporation.

The Israeli R&D center was opened after the acquisition of Percutaneous Valve Technologies in 2003 and focuses on the development of percutaneous heart valves and other percutaneous techniques for heart valve repair and replacement.The Edwards Israel Innovation Center (EIIC) focuses on developing early-stage cardiovascular technologies.

Our passion, ingenuity, collaboration, and new ways of thinking enable us to develop devices and therapies that help patients around the world.

Our commitment to a diverse and inclusive work culture welcomes all perspectives to help us thrive.

We invite mission-driven employees in engineering, quality assurance, regulatory affairs, cyber security & data analytics and more to join us to impact patients' lives.